Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance

Antiviral Therapy

Volumn 12, Issue 4, 2007, Pages 563-570

  Lataillade, Max ^a   Chiarella, Jennifer ^a   Kozal, Michael J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ELVITEGRAVIR; GS 9137; INTEGRASE; INTEGRASE INHIBITOR; L 708; L 731; L 810; L 870; L 906; L 988; MK 0518; MK 2048; RALTEGRAVIR; UNCLASSIFIED DRUG; V 165; Y BOX BINDING PROTEIN 1;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; DNA INTEGRATION; DNA SEQUENCE; DRUG CLASSIFICATION; DRUG SENSITIVITY; ENZYME BINDING; ENZYME INHIBITION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS STRAIN;

AMINO ACID SEQUENCE; CONSENSUS SEQUENCE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, GENETIC; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 34447263572     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4:236-248.
2. Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 2006; 7:489-501.
3. Van Maele B, Debyser Z. HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral Proteins. AIDS Rev 2005; 7:26-43.
4. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci U S A 2002; 99:6661-6666.
5. Hazuda DJ. Inhibitors of human immunodeficiency virus type I. Retrovirology 2006; 3 Suppl 1:S7.
6. Debyser Z, Hombrouck A, Witvrouw M, De Rijck J, Hendrix J. Virus evolution reveals LEDGF/p75 as the sole mediator of chromosomal tethering. 14th Conference on Retroviral and Opportunistic Infections 2007, Los Angeles CA, USA. Feb 25-28; Abs. 15
7. Hombrouck A, De Rijck J, Busschots K, Christ F Debyser Z. Structure-function analysis of the interface between HIV-1 integrase and the cellular co-factor LEDGF/p75. 14th Conference on Retroviral and Opportunistic Infections 2007, Los Angeles CA, USA. Feb 25-28; Abs. 189.
8. Cooper D, Gatell J, Rockstroh J, Katlama C, Isaacs R, Nguyen B. Results of BENCHMRK-1, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviral and Opportunistic Infections. 25-28 February 2007, Los Angeles CA, USA. Abs. 105aLB.
9. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviral and Opportunistic Infections. 25-28 February 2007, Los Angeles CA, USA. Abs. 105bLB.
10. Zolopa AR, Mullen M, Berger D, Ruane P, Hawkins T. The HIV integrase inhibitor GS-9137 demonstrates potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviral and Opportunistic Infections. 25-28 February 2007, Los Angeles CA, USA. Abs. 143LB.
11. M Lataillade, J Chiarella, MJ Kozal. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2006; 11:S28.
12. Llano M, Vanegas M, Hutchins N, Thompson D, Delgado S, Poeschla EM. Identification and characterization of the chromatin-binding domains of the HIV-1 integrase interactor LEDGF/p75. J Mol Biol 2006; 360:760-773.
13. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A. 2005; 102:17308-17313.
14. Billich A. S-1360 Shinogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4:206-209
15. Witvrouw M, Hantson A, Hombrouck A, et al. Multiple mutations in HIV-1 integrase confer resistance to the PyranoDipyrimidine V-165. 5th HIV DRP Symposium on Antiretroviral Drug Resistance, 14-17 November 2004 Chantilly, VA, USA. Abstract # 18.
16. Pannecouque C, Pluymers W, Van Maele B, et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 2002; 12:1169-1177.
17. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650.
18. Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D 2007; 8:155-168.
19. Hazuda DJ, Anthony NJ, Gomez RP, et. al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 2004; 101:11233-11238.
20. Kodama E, Shimura K, Sakagami Y, et al. In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30, 2006, San Francisco, CA, USA. Abstract H-254.
21. Grinsztejn B, Nguyen, BY, Katlama C, et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy September 27-30 2006, San Francisco CA, USA. Abstract H1670b.
22. Bonnenfant S, Thomas CM, Vita C, et al. Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. J Virol 2004; 78:5728-5736.
23. Mousnier A, Leh H, Mouscadet JF, Dargemont C. Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol Pharmacol 2004; 66:783-788.
24. Di Santo R, Costi R, Roux A, et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J Med Chem 2006; 49:1939-1945.
25. Marchand C, Johnson AA, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). Mol Pharmacol 2003; 64:600-609.
26. Lee DJ, Robinson WE Jr. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to DKA integrase inhibitors impairs HIV replication and integration and confers cross resistance to L-chicoric acid. J Virol, 2004; 78:5835-5847.
27. Barreca ML, Lee KW, Chimirri A, Briggs JM. Molecular dynamics of the wild type and double mutant HIV-1 integrase complexed with 5-CITEP inhibitor: mechanism for inhibition and drug resistance. Biophys J 2003; 84:1450-1463.
28. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-57.
29. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2:753-759.
30. De Meyer S, Hill A, De Baere I, et al. Effect of baseline susceptibility and on-treatment mutations on TMC114 and control PI efficacy: preliminary analysis of data from Pi-experienced patients from POWER 1 and POWER 2. 13th Conference on Retroviral and Opportunistic Infections 2006, Denver, CO, USA. Abstract #157.
31. Kozal MJ, Huppler Hullsiek K, Leduc R, et al. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients enrolling in clinical trials. Antivir Ther 2006; 11:457-463.
32. Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77:11459-11470.
33. Fikkert V, Hombrouk A, Van Remoortel B, et al. Multiple mutations in HIV-1 IN confer resistance to the clinical trial drug S-1360. AIDS 2004; 18:2019-2028.
34. Jones G, Ledford R, Yu F, Miller M, Tsiang M, McColl D. Resistance Profile of HIV-1 Mutants in vitro Selected by the HIV-1 Integrase Inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviral and Opportunistic Infections. 25-28 February 2007, Los Angeles CA, USA. Abstract 627.
35. Wai J, Fisher T, Embrey M, et al. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles. 14th Conference on Retroviral and Opportunistic Infections 25-28 February 2007, Los Angeles CA, USA. Abstract 87.
36. Hackett J, Jr, Swanson P, Harris B, Holzmayer V, Yamaguchi J, Bodelle P, Brennan C, Schochetman G, and Devare S. Comprehensive evaluation of HIV-1 integrase gene diversity in group M, N, and O viruses. 12th Conference on Retroviral and Opportunistic Infections, 22-25 February 2005, Boston MA, USA. Abstract LB#366.
37. Zioni, R, Rhee S, Liu T, Shafer R. Natural variation of HIV-1 group M integrase: implications for integrase inhibitor therapy. 14th Conference on Retroviral and Opportunistic Infections 25-28 February 2007, Los Angeles CA, USA. Abstract 623.
38. Lu R, Limon A, Ghory HZ, Engelman A. Genetic analyses of DNA-binding mutants in the catalytic core domain of human immunodeficiency virus type 1 integrase. J Virol 2005; 79:2493-2505.
39. Llano M, Saenz DT, Meehan A, et al. An essential role for LEDGF/p75 in HIV integration. Science 2006; 314:461-464
40. Emiliani S, Mousnier A, Busschots K, Maroun M, Van Maele B, Tempe D. Integrase mutants defective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem 2005; 280:25517-25523.